// App-Quantinova.ai

1066 : Comparison Of Plasma Kallikrein Inhibition By The Endogenous C1-Inhibitor Versus DX-2930, a Monoclonal Antibody Inhibitor

Researchers

Presenter

  • Daniel J Sexton

Principal Investigators

  • Jon A Kenniston

  • Ryan R Faucette

  • Andrew E Nixon

  • Chris TenHoor

  • Yung Chyung

  • Burt Adelman

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Dyax Corp.

Study Components

Therapeutic Area

  • Genetic Disorder

  • Blood/haematological Diseases

Disease

  • Hereditary angioedema

  • Venous thrombosis

  • High molecular weight kininogen deficiency

Biomarkers

  • N/A

Drug/Treatment

  • DX2930

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved